echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Progress in the study of immunocheckpoint inhibitors targeting tumor

    Progress in the study of immunocheckpoint inhibitors targeting tumor

    • Last Update: 2019-08-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, tumor immunotherapy has developed rapidly, and many tumor patients have benefited from it But clinical data show that immunotherapy is very inefficient for a considerable number of tumor patients, and shows strong side effects, which makes the immune system attack some normal tissues and organs of the human body, sometimes even life-threatening With the emergence of more and more tumor immunotherapy drugs and the development of immunocombination therapy, it is increasingly urgent to improve the efficacy of immunosuppressant and reduce its side effects In order to solve this problem, a team led by Wang Feng, a researcher of the Institute of Biophysics, Chinese Academy of Sciences, and Cao Yu, a researcher of Shenzhen Graduate School of Peking University, and Peter Schultz, a researcher of Scripps Institute in the United States, proposed for the first time to combine tumor targeting recognition with immunosuppression, so that immunosuppression can effectively target melanoma tumors Microcirculation and play an immunomodulatory role Recently, relevant research results were published in the proceedings of the National Academy of Sciences (PNAs) In this study, ndp-msh, a melanocyte stimulating hormone analogue, was covalently linked with PD-L1 antibody by chemical linkage to form a bispecific antibody ndp-msh - α PD-L1 The results showed that ndp-msh - α PD-L1 had strong binding activity to MC1R receptor and PD-L1 on melanoma cell surface In the mouse melanoma model, tumor targeted immunocheckpoint inhibitor ndp-msh-α PD-L1 showed more significant tumor growth inhibition activity than PD-L1 at the same dose A series of experiments have proved that the tumor growth inhibitory activity of ndp-msh-α PD-L1 is positively correlated with the number of infiltrating lymphocytes in the tumor, revealing the mechanism of ndp-msh-α PD-L1 inhibiting tumor growth: by inhibiting its immune escape mechanism in the tumor microenvironment, increasing the number of infiltrating lymphoid T cells and enhancing the immune response, the tumor can be inhibited Purpose of growth The significant effect of ndp-msh-α PD-L1 has established the foundation for the future application of tumor targeted immunosuppressive checkpoint inhibitors in different kinds of solid tumors Wang Feng's team is also committed to continuously finding and optimizing the framework of bispecific antibodies targeting different tumors, hoping to further improve the efficacy and safety of tumor targeted immunosuppressive checkpoint inhibitors.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.